<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290379</url>
  </required_header>
  <id_info>
    <org_study_id>TNX-IS-T101</org_study_id>
    <nct_id>NCT02290379</nct_id>
  </id_info>
  <brief_title>Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers</brief_title>
  <official_title>A Single-Center, Randomized, Double-blind, Placebo-controlled, Phase 1, Single Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of TNX-201 Capsules in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tonix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tonix Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, randomized, double-blind, placebo-controlled, single ascending dose, safety
      and tolerability study of TNX-201 capsules in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, randomized, double-blind, placebo-controlled, single ascending dose, safety
      and tolerability study of TNX-201 capsules in healthy volunteers. Three successive cohorts
      are planned with doses of TNX-201 capsules, 35 mg, 70 mg, and 140 mg, respectively. Each
      cohort will consist of 15 subjects, and subjects will be randomly assigned to TNX-201,
      racemic isometheptene, or placebo capsules.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of isometheptene or metabolites.</measure>
    <time_frame>60 minutes pre-dose and multiple timepoints up to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse events</measure>
    <time_frame>60 minutes pre-dose and multiple timepoints up to 48 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TNX-201 35 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: TNX-201 35 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNX-201 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: TNX-201 70 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNX-201 140 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: TNX-201 140 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Racemic isometheptene 70 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator: Racemic Isometheptene 70 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNX-201 35 mg</intervention_name>
    <description>Drug: TNX-201 35 mg</description>
    <arm_group_label>TNX-201 35 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNX-201 70 mg</intervention_name>
    <description>Drug: TNX-201 70 mg</description>
    <arm_group_label>TNX-201 70 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNX-201 140 mg</intervention_name>
    <description>Drug: TNX-201 140 mg</description>
    <arm_group_label>TNX-201 140 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racemic isometheptene 70 mg</intervention_name>
    <description>Active Comparator: Racemic isometheptene 70 mg</description>
    <arm_group_label>Racemic isometheptene 70 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, ≥ 18 and ≤ 55 years of age on the day of randomization. NOTE: At least
             6 female subjects need to be randomized in each cohort.

          2. Body mass index (BMI) ≥18.5 and ≤33.0

          3. Non-tobacco users (no use of tobacco- or nicotine- containing products within 3 months
             prior to study drug administration)

        Exclusion Criteria:

          1. Any clinically significant abnormality or clinically significant abnormal laboratory
             test results found at Screening or Day -1, or a positive test for HBsAg, HCAb, or HIV
             found at Screening

          2. Positive urine drug screen (including alcohol, tetrahydrocannabinol (THC), cocaine,
             amphetamines, and opiates) or urine cotinine test at Screening or on Day -1

          3. Known or suspected hypersensitivity to isometheptene mucate or any excipients used in
             the formulations.

          4. Positive serum pregnancy test at Screening or Day -1

          5. Any reason, in the opinion of the Principal Investigator (PI) or the sponsor's Medical
             Monitor, to prevent the subject from participating in the study

          6. Clinically significant ECG abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

